WestChina-Frontier
Founded in 2000, WestChina-Frontier is a premier GLP-compliant research organization specializing in non-clinical drug development and evaluation. The company holds multiple international and national accreditations, including NMPA GLP certification, U.S. FDA GLP inspections, OECD GLP certification, AAALAC accreditation, CAP certification, and CNAS accreditation.
With over two decades of experience, WestChina-Frontier has established a standardized, internationally recognized, large-scale, and data-driven platform for non-clinical drug research. It serves as a key technical partner in new drug development and a leading innovation hub for drug evaluation technologies in China.
WestChina-Frontier operates approximately 80,000 square meters of state-of-the-art, GLP-compliant laboratory facilities. The institution is supported by a team of over 1,400 skilled professionals and is equipped with cutting-edge analytical and testing instruments. It has implemented a Laboratory Information Management System (LIMS) aligned with global standards, enabling a high level of data integrity and operational efficiency.
WestChina-Frontier provides a comprehensive portfolio of non-clinical services, including pharmacology, pharmacokinetics and toxicology studies for small molecules, biologics, vaccines, cell and gene therapies. Research capabilities cover a broad range of laboratory animal models, including rodents, rabbits, dogs, miniature pigs, and non-human primates. In addition, the company offers integrated bioanalytical services, including method development, along with immunogenicity assessments.
